For obstructive sleep apnea patients impacted by the Philips recall, ProSomnus Sleep Technologies has issued a statement saying it has a “scalable rapid, seven-day, production schedule to get patients into therapy faster. Capacity can be expanded easily to accommodate this crisis.”
“The objective is to help sleep physicians and dental sleep providers to get affected patients back into safe, comfortable, and effective therapy,” says Len Liptak, CEO of ProSomnus, in a release. “It is understandable that many affected patients may prefer non-CPAP alternatives. We want the sleep medicine community to know that ProSomnus is a partner they can trust for oral appliance therapy.”
Sleep physician Edward T. Sall, MD, DDS, MBA, medical director at ProSomnus says in a release, “Because of the current limited availability of machines and a complex payment structure for replacing them, ProSomnus OSA Therapy is an exceptional solution. This California medical device manufacturer can scale their artificial intelligent design and robotic manufacturing….My recent AASM (American Academy of Sleep Medicine) poster abstract also demonstrates the efficacy and effectiveness of these devices for mild moderate and select severe patients.”
Mark T. Murphy, DDS, DABDSM, lead faculty clinical education, says in a release, “Never has there been a better time to utilize this valuable alternative solution to enhance the lives of so many affected by this recall. Treating physicians should engage ProSomnus qualified providers to quickly solve this crisis.”
